Kunxian capsule alleviates podocyte injury and proteinuria by inactivating β-catenin in db/db mice

BackgroundDiabetic kidney disease (DKD) remains the primary cause of end-stage renal disease (ESRD) globally, but treatment options are limited. Kunxian capsule (KXC) has been utilized for the treatment of autoimmune diseases and IgA nephropathy in China. However, its effect on DKD remains poorly in...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Frontiers in Medicine
المؤلفون الرئيسيون: Bo Jin, Jing Liu, Yan Zhu, Jian Lu, Qingyan Zhang, Yan Liang, Qiuyuan Shao, Chunming Jiang
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Frontiers Media S.A. 2023-06-01
الموضوعات:
الوصول للمادة أونلاين:https://www.frontiersin.org/articles/10.3389/fmed.2023.1213191/full

مواد مشابهة